Brivanib alaninate

Phase 3Small molecule

Brivanib alaninate is one of 149 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Endometrial CancerActive, not recruiting

Cervical CancerActive, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Braftovi

Pfizer

Phase 3

11 2

Cyramza

Eli Lilly

Phase 3

2 3

Folinic Acid

Roche

Phase 3

17 4

Trifluridine/tipiracil

AbbVie

Phase 3

13 5

Ofev

Boehringer Ingelheim

Phase 3

3 6

Legalon

BBukwang Pharmaceutical

Phase 3

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Phase 3

1 8

Vatalanib

Novartis

Phase 3

2 9

XL092

Roche

Phase 3

1 10

Donafenib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00640471·750 enrolled

Cervical Cancer1 trial

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT01267253·31 enrolled

Renal Cell Carcinoma1 trial

Brivanib Metastatic Renal Cell Carcinoma

Terminated·—·Phase 2·NCT01253668·10 enrolled

Advanced Cancers1 trial

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00798252·111 enrolled

Endometrial Cancer1 trial

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00888173·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Brivanib alaninate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brivanib alaninate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brivanib alaninate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGynecologic Oncology Group

Brivanib alaninate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Cervical Cancer1 trial

Renal Cell Carcinoma1 trial

Advanced Cancers1 trial

Endometrial Cancer1 trial

References

Drug Info

Quick Facts

Related News